Symptomatic treatment of multiple sclerosis

被引:105
作者
Henze, T.
Rieckmann, P.
Toyka, K. V.
机构
[1] Reha Zentrum Nittenau, Rehabil Zentrum Neurol, DE-93149 Nittenau, Germany
[2] Univ Wurzburg, Dept Neurol, D-8700 Wurzburg, Germany
关键词
multiple sclerosis; symptomatic treatment; consensus guidelines; expert opinion; evidence-based medicine;
D O I
10.1159/000095699
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:78 / 105
页数:28
相关论文
共 273 条
[31]  
Büttner U, 1999, NERVENARZT, V70, P371
[32]   Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm [J].
Çakmur, R ;
Ozturk, V ;
Uzunel, F ;
Donmez, B ;
Idiman, F .
JOURNAL OF NEUROLOGY, 2002, 249 (01) :64-68
[33]   Dysphagia in multiple sclerosis - prevalence and prognostic factors [J].
Calcagno, P ;
Ruoppolo, G ;
Grasso, MG ;
De Vincentiis, M ;
Paolucci, S .
ACTA NEUROLOGICA SCANDINAVICA, 2002, 105 (01) :40-43
[34]   Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder [J].
Cardozo, L ;
Lisec, M ;
Millard, R ;
Trip, OV ;
Kuzmin, I ;
Drogendijk, TE ;
Huang, M ;
Ridder, AM .
JOURNAL OF UROLOGY, 2004, 172 (05) :1919-1924
[35]   Efficacy of trospium chloride in patients with detrusor instability:: a placebo-controlled, randomized, double-blind, multicentre clinical trial [J].
Cardozo, L ;
Chapple, CR ;
Toozs-Hobson, P ;
Grosse-Freese, M ;
Bulitta, M ;
Lehmacher, W ;
Strösser, W ;
Ballering-Brühl, B ;
Schäfer, M .
BJU INTERNATIONAL, 2000, 85 (06) :659-664
[36]   The possible value of ascorbic acid as a prophylactic agent for urinary tract infection [J].
Castello, T ;
Girona, L ;
Gomez, MR ;
Mur, AM ;
Garcia, L .
SPINAL CORD, 1996, 34 (10) :592-593
[37]   A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate [J].
Chancellor, MB ;
Appell, RA ;
Sathyan, G ;
Gupta, SK .
CLINICAL THERAPEUTICS, 2001, 23 (05) :753-760
[38]  
CHAPPLE C, 2004, EUR UROL SUPPL, V3, pA512
[39]   Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder [J].
Chapple, CR ;
Rechberger, T ;
Al-Shukri, S ;
Meffan, P ;
Everaert, K ;
Huang, M ;
Ridder, A .
BJU INTERNATIONAL, 2004, 93 (03) :303-310
[40]   Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia [J].
Chartier-Kastler, EJ ;
Bosch, JLHR ;
Perrigot, M ;
Chancellor, MB ;
Richard, F ;
Denys, P .
JOURNAL OF UROLOGY, 2000, 164 (05) :1476-1480